Dermal fillers, also known as injectable fillers or soft tissue fillers, are categorized as medical devices by the U.S. FDA. Dermal fillers are used to reduce wrinkles and smoothen skin appearance caused by ageing, acne or scars. The application areas are face including Nasolabial fold, cheeks, lips, corners of the eye, and dorsal area of hands.
North America and Europe dermal fillers market is estimated to account for US$ 2981.1 Mn in terms of value by the end of 2027.Increasing geriatric population is expected to propel growth of North America and Europe dermal fillers market over the forecast period. For instance, according to the U.S. Census Bureau, geriatric population in the U.S. is expected to reach 77 million by 2035.
Browse Summary of the Research Report– https://www.coherentmarketinsights.com/market-insight/north-america-and-europe-dermal-filler-market-3522
Moreover, increasing healthcare expenditure is also expected to aid in growth of the market. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5% per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027.North America region held dominant position in North America and Europe dermal fillers market in 2019, accounting for 59.6% share in terms of value, followed by 2027.
High cost of physician services for procedures and the need for multiple sessions for desired results is expected to hinder growth of North America and Europe dermal fillers market. The service cost of physicians or surgeons is around 40 to 50% of the dermal filler cost. The fillers like HA, PLLA, CaHA and collagen are biodegradable and last for 3 to 24 months. Most of them are naturally present in body and therefore get degraded quickly. This in turn requires multiple sessions for attaining the desired results, which further increases the overall cost of the procedure.
Majority of the dermal fillers currently available are absorbable / bio degradable except for PMMA fillers. Biodegradable fillers last for 3 to 24 months, whereas PMMA fillers last for 4-5 years. This makes the procedure repetitive after the certain time, which may lead to a shift towards surgical facial rejuvenation instead of dermal fillers, which limits growth of the market.
R&D in dermal fillers is also expected aid in growth of the market. For instance, according to a new study, ‘An Objective, Quantitative, Dynamic Assessment of Hyaluronic Acid Fillers That Adapt to Facial Movement’, published in the February 2020 issue of Plastic and Reconstructive Surgery, dermal fillers also restore a more youthful pattern of facial movement and expressiveness apart from filling wrinkles.
Absorbable segment in North America and Europe dermal fillers market was valued at US$ 1,723.7 Mn in 2019 and is expected to reach US$ 2,936.9 Mn by 2027 at a CAGR of 6.9% during the forecast period.The market is witnessing high adoption of injectable dermal fillers as a minimally invasive approach to reduce facial lines and wrinkles. For instance, according to American Society of Plastic Surgeons (ASPS), around 2.7 million dermal filler injection procedures were performed in 2018 in the U.S.
Dermal fillers are also used in enhancement of dorsal area of hands and for HIV-induced facial lipoatrophy. CaHA fillers are used for the treatment of paralyzed vocal cords and dentists also can perform dermal filler procedure for facial rejuvenation to improve post dental procedures facial aesthetics.Hand rejuvenation is gaining preference among the populace. However, there are few treatments approved for the correction of volume loss in the hand, which include application of PLA and CaHA.
Major players operating in North America and Europe dermal fillers market include, Galderma Pharma S.A., Sinclair Pharma plc., Allergan Plc., Anika Therapeutics Inc., Merz Pharma GmbH & Co. KGaA, Suneva Medical Inc., Teoxane Laboratories Inc., Prollenium Medical Technologies Inc., Adoderm GmbH, and Laboratoires Vivacy SAS.
Major players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in January 2020, Revance Therapeutics, Inc. signed an agreement with TEOXANE SA for distribution of TEOXANE SA’s Resilient Hyaluronic Acid technology in the U.S.
In January 2020, Histogen, Inc., a regenerative medicine company, expanded its partnership with Allergan, Inc., under which Allergan acquired exclusive rights to incorporate and commercialize Histogen's cell conditioned media in microdermabrasion therapies and exclusive rights to new Histogen intellectual property in the aesthetic field.
Request A Sample Copy link:- https://www.coherentmarketinsights.com/insight/request-sample/3522
ContactUs:
Mr.Shah
Coherent Market ,Insights
10014thAve,
#3200
Seattle,WA98154
Tel:+1-206-701-6702
Email: [email protected]